Digital solutions that put patients at forefront of safety processes
Capture relevant, essential and complete data at first interaction
Maximise the value of initial contact and reduce low value follow up
Solutions that ensure REMS and RMP commitments are met and are future proofed
Debating the Future of Spontaneous Reporting - Dr. Andrew Rut, CEO and Founde...MyMeds&Me
MyMeds&Me CEO Andrew Rut proposes the debate motion, “With the changes in society and increased use of electronic media, the role of the health professional in Yellow Card reporting will be diminished” at the MHRA Scientific Conference in Edinburgh - this year commemorating the 50th anniversary of the Yellow Card reporting scheme.
It is well recognized that patient reports enhance signal detection and enable earlier recognition of safety issues . Given the significant level of under-reporting of adverse events by HCPs (Only between <1% - 6% of suspected ADRs experienced by patients are reported) and the apparent appetite from patients to share their experiences, as seen in social media and patient forums globally, we believe that we need to simplify reporting processes and enable all patients to report online with ease.
Clean data direct from source, without alteration, is the life-blood of drug safety organisations. PV specialists evaluating the safety of medicines rely upon rapid access to clean, complete, consistent data from source and patients ultimately are that source. It is essential to capture this data and therefore build a true picture for future signal detection activities.
Managing an end to end Pharmacovigilance system from affiliates to regulatory...MyMeds&Me
MyMeds&Me CEO Dr. Andrew Rut explores how technology can help address the challenges facing Pharmacovigilance teams.
He reviews how the latest intake technology can influence end-user experience and effectiveness, as well as internal value & efficiency.
He concludes that a focus on simplifying case intake re-shapes the traditional PV system, enabling Pharma companies to reap significant process and efficiency benefits.
Driving risk management through intelligent intake technologyMyMeds&Me
MyMeds&Me CEO Dr. Andrew Rut presents the case for driving risk management through intelligent intake technology.
Andrew outlines how pharmacovigilance professionals can move from passive to active PV fuelling better decision-making.
This presentations covers:
Pharmacovigilance and risk management challenges
Evolving PV landscape
Addressing the challenges
Reviewing the possible architecture
A glimpse of the technology
Implementation benefits
For more info see: www.mymedsandme.com
Why Health Systems Must Use Data Science to Improve OutcomesHealth Catalyst
In today’s improvement-driven healthcare environment, organizations must ensure that improvement measures help them reach desired outcomes and focus on the opportunities with optimal ROI. With data science-based analysis, health systems leverage machine learning to determine if improvement measures align with specific outcomes and avoid the risk and cost of carrying out interventions that are unlikely to support their goals.
There are four essential reasons that insights from data science help health systems implement and sustain improvement:
Measures aligned with desired outcomes drive improvement.
Improvement teams focus on processes they can impact.
Outcome-specific interventions might impact other outcomes.
Identifies opportunities with optimal ROI.
mHealth Israel_Future of Integrated Individualized Healthcare_Roche DiagnosticsLevi Shapiro
Presentation by Alexandra Eberhard, Sr. Director, Global Business Development, Roche Diagnostics on the "Future of Integrated Individualized Healthcare". Includes background about Roche Diagnostics and investments in innovation. Overview of Roche products and solutions with a portfolio covering the entire spectrum of diagnostics users. Emphasis on the triple aim of healthcare- The power of data and technology to enable the transformation from volume- to value-based healthcare. Interest in data for Pharma - drive more efficient R&D; DIA - develop novel patient care Dx solutions. Focus on the needs of labs, physicians & payers for better patient health. A suite of digital solutions that improve clinical & business outcomes. Suite of solutions to optimize the lab. Translating data into insights to achieve financial goals. A move from volume- to value-based care. New opportunities in the disease continuum- Holistic solutions approach. Expanding the focus towards earlier in the patient journey. Doing now what patients need next. Contact Alexandra Vallon-Eberhard, PhD MBA; Sr. Director Global Business Development; Diagnostics Lead for Innovation in Israel; Based in Basel, Switzerland; Email: alexandra.vallon_eberhard@roche.com
Care Management Part 2 - A Critical Component of Effective Population HealthHealth Catalyst
Care management plays a central role in the world of value-based reimbursements, at-risk contracts, and population health management. Such programs require high-touch and resource-intensive care as teams work to deliver on the substantial promise of delivering patient care improvements while reducing costs.
Evidence Based Clinical Decision Support – An Enabler for Clinicians in 21st Century by Dr. Lalit Singh, Director for Content & Product Strategy, Elsevier, India
Debating the Future of Spontaneous Reporting - Dr. Andrew Rut, CEO and Founde...MyMeds&Me
MyMeds&Me CEO Andrew Rut proposes the debate motion, “With the changes in society and increased use of electronic media, the role of the health professional in Yellow Card reporting will be diminished” at the MHRA Scientific Conference in Edinburgh - this year commemorating the 50th anniversary of the Yellow Card reporting scheme.
It is well recognized that patient reports enhance signal detection and enable earlier recognition of safety issues . Given the significant level of under-reporting of adverse events by HCPs (Only between <1% - 6% of suspected ADRs experienced by patients are reported) and the apparent appetite from patients to share their experiences, as seen in social media and patient forums globally, we believe that we need to simplify reporting processes and enable all patients to report online with ease.
Clean data direct from source, without alteration, is the life-blood of drug safety organisations. PV specialists evaluating the safety of medicines rely upon rapid access to clean, complete, consistent data from source and patients ultimately are that source. It is essential to capture this data and therefore build a true picture for future signal detection activities.
Managing an end to end Pharmacovigilance system from affiliates to regulatory...MyMeds&Me
MyMeds&Me CEO Dr. Andrew Rut explores how technology can help address the challenges facing Pharmacovigilance teams.
He reviews how the latest intake technology can influence end-user experience and effectiveness, as well as internal value & efficiency.
He concludes that a focus on simplifying case intake re-shapes the traditional PV system, enabling Pharma companies to reap significant process and efficiency benefits.
Driving risk management through intelligent intake technologyMyMeds&Me
MyMeds&Me CEO Dr. Andrew Rut presents the case for driving risk management through intelligent intake technology.
Andrew outlines how pharmacovigilance professionals can move from passive to active PV fuelling better decision-making.
This presentations covers:
Pharmacovigilance and risk management challenges
Evolving PV landscape
Addressing the challenges
Reviewing the possible architecture
A glimpse of the technology
Implementation benefits
For more info see: www.mymedsandme.com
Why Health Systems Must Use Data Science to Improve OutcomesHealth Catalyst
In today’s improvement-driven healthcare environment, organizations must ensure that improvement measures help them reach desired outcomes and focus on the opportunities with optimal ROI. With data science-based analysis, health systems leverage machine learning to determine if improvement measures align with specific outcomes and avoid the risk and cost of carrying out interventions that are unlikely to support their goals.
There are four essential reasons that insights from data science help health systems implement and sustain improvement:
Measures aligned with desired outcomes drive improvement.
Improvement teams focus on processes they can impact.
Outcome-specific interventions might impact other outcomes.
Identifies opportunities with optimal ROI.
mHealth Israel_Future of Integrated Individualized Healthcare_Roche DiagnosticsLevi Shapiro
Presentation by Alexandra Eberhard, Sr. Director, Global Business Development, Roche Diagnostics on the "Future of Integrated Individualized Healthcare". Includes background about Roche Diagnostics and investments in innovation. Overview of Roche products and solutions with a portfolio covering the entire spectrum of diagnostics users. Emphasis on the triple aim of healthcare- The power of data and technology to enable the transformation from volume- to value-based healthcare. Interest in data for Pharma - drive more efficient R&D; DIA - develop novel patient care Dx solutions. Focus on the needs of labs, physicians & payers for better patient health. A suite of digital solutions that improve clinical & business outcomes. Suite of solutions to optimize the lab. Translating data into insights to achieve financial goals. A move from volume- to value-based care. New opportunities in the disease continuum- Holistic solutions approach. Expanding the focus towards earlier in the patient journey. Doing now what patients need next. Contact Alexandra Vallon-Eberhard, PhD MBA; Sr. Director Global Business Development; Diagnostics Lead for Innovation in Israel; Based in Basel, Switzerland; Email: alexandra.vallon_eberhard@roche.com
Care Management Part 2 - A Critical Component of Effective Population HealthHealth Catalyst
Care management plays a central role in the world of value-based reimbursements, at-risk contracts, and population health management. Such programs require high-touch and resource-intensive care as teams work to deliver on the substantial promise of delivering patient care improvements while reducing costs.
Evidence Based Clinical Decision Support – An Enabler for Clinicians in 21st Century by Dr. Lalit Singh, Director for Content & Product Strategy, Elsevier, India
NCQA’s Accreditation process provides payers with a comprehensive framework to improve quality of care and services. It allows members and employers to compare health plan performance across various plans and against industry benchmarks. NCQA accreditation has 3 parts – HEDIS, Patient experience CAHPS measures and NCQA standards
Patients recognize the benefits of technology-enhanced care, yet only 1 out of 10 use remote patient monitoring today. Read three keys to adoption. https://accntu.re/3fnEy6r
Providers need to move towards real-time analytics that have become critical to demonstrate their quality of care, as reimbursement by government programs can be contingent upon how providers are measured in “Quality of Care”. For example, the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015, also called the Permanent Doc Fix, changes the way Medicare doctors are reimbursed with the implementation of a merit based incentive. The performance-based pressure is huge, which makes it imperative that every provider consider technology solutions. Read more at https://www.solix.com/solutions/data-driven-solutions/healthcare/
Three Strategies to Deliver Patient-Centered Care in the Next NormalHealth Catalyst
Juggling financial demands, uncertain healthcare legislation, and COVID-19 can distract healthcare leaders from the most important aspect of care—patients. Delivering patient-centered care in this volatile market can be challenging, especially when traditional healthcare methods (e.g., in-person visits) are on hold. These sudden disruptions to routine care have highlighted the importance of keeping patients at the center of care, whether care delivery is in-person or virtual. Health systems can manage competing priorities, adjust to pandemic-induced changes, and deliver patient-centered care by focusing on three strategies:
Improve the patient experience.
Implement the Meaningful Measures Initiative.
Transition in-person visits to virtual.
United States Diagnostics Market Size, Share, Trend and Forecast 2026 | TechS...TechSci Research
According to #TechSci Research report, United States Diagnostics Market stood at USD30.08billion in 2020 and is expected to grow at a steady rate of 5.17% during the forecast period.
Gain More Insight: https://bit.ly/3wWI0do
Get Sample Report: https://bit.ly/3ltFdo6
Website: https://www.techsciresearch.com/
Market Research News: https://techsciblog.com/
Opportunity analysis uses data to identify potential improvement initiatives and quantifies the value of these initiatives—both in terms of patient care benefits and financial impact. This process is an effective way to find unwarranted and costly clinical variation and, in turn, develop strategies to reduce it, improving outcomes and saving costs along the way. Standardizing the opportunity analysis process makes it repeatable and prioritizes actionable opportunities.
Quarterly opportunity analysis should follow four steps:
Kicking off the analysis by getting analysts together to do preliminary analysis and brainstorm.
Engaging with clinicians to identify opportunities and, in the process, get clinician buy in.
Digging deeper into the suggested opportunities to prioritize those that offer the greatest benefits.
Presenting findings to the decision makers.
Introducing the Health Catalyst Monitor™ Patient Safety Suite Surveillance Mo...Health Catalyst
Unlike the standard post-event reporting process, the Patient Safety Monitor Suite: Surveillance Module is a trigger-based surveillance system, enabled by the unique industry-first technological capabilities of the Health Catalyst Data Operating System platform, including predictive analytic models and AI. Additionally, once listed, the Health Catalyst PSO will create a secure and safe environment where clients can collect and analyze patient safety events to learn and improve, free from fear of litigation. Coupled with patient safety services, an organization’s active all-cause harm patient safety system is fully enabled to deliver measurable and meaningful improvements.
Good surfers are the consummate analysts. They dynamically process streams of seemingly unrelated information bypassing lesser opportunities, then strategically selecting the perfect wave.
The ability to tease out genuine opportunities amidst a tumult of noise is a hallmark of great analysts. By viewing these slides you will learn:
- The human elements of a great analyst.
- How to re-frame the role of technology in analysis.
- Healthcare knowledge required to maximize the value of a healthcare analyst.
John Wadsworth's (Senior Vice President of Client Engagement, Health Catalyst) engaging presentation style leverages simple and fun analogies to galvanize key concepts for technical, clinical, and executive audiences alike. Join us as he brings principles from the world of surfing and applies them to healthcare analytics.
At eClinicalWorks, we are 5,000 employees dedicated to improving healthcare together with our customers. More than 130,000 physicians nationwide — and more than 850,000 medical professionals around the globe — rely upon us for comprehensive clinical documentation, along with solutions for Practice Management, Population Health, Patient Engagement, and Revenue Cycle Management.
Transforming Clinical Practice InitiativeCitiusTech
The Transforming Clinical Practice Initiative (TCPI) is designed to help small practices and clinicians achieve large-scale health transformation. The initiative is designed to support more than 140,000 clinician practices over four years duration in sharing, adapting and further developing their comprehensive quality improvement strategies. The TCPI is one part of a unique strategy advanced by the Affordable Care Act to strengthen the quality of patient care and manage health care expenditures, ultimately saving the taxpayer from substantial costs. This document describes the initiative in detail with the type of participants, eligibility and reporting requirements of the participants. Understanding the implementation of this initiative not only helps clinicians, but opens up a huge market for Healthcare IT companies offering the products and services like EHR implementation, Integration, EHR/ Data Migration, Implementation of HIE etc.
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
Technology is slowly but surely penetrating the healthcare industry in general and the clinical trials sector in particular. New and advanced solutions offer a variety of possibilities aimed to both improving existing processes and creating new and more efficient ones. And on top of all stands the desire to make clinical trials more patient centric.
In all of this, even though some of the technologies have yet to mature enough to meet the high quality standards necessary, it is important to know them and begin imagining the promise they hold for clinical trials.
Virtual health is supporting continuing efforts to further humanize health care by extending and expanding the concept of a patient-centric care delivery model into one that is truly life-centric.
Virtual health uses telecommunication and networked technologies to connect clinicians with patients (and with other clinicians) to remotely deliver health care services and support well-being. For providers, committing to virtual health at a personal and organizational level affords ever-increasing opportunities to deliver the right care at the right time in the right place, in a connected and coordinated manner.
By strengthening and facilitating a therapeutic alliance between clinicians and patients, virtual health is an important step on our continuous journey to humanize health care. It works within and around a patient’s life, as opposed to their sickness, to deliver care when, where, and how they need and want it. Also, virtual health works its way into consumers’ daily routines by being embedded in electronic devices associated with living life (e.g., smartphones and personal computers) more so than caring for sickness.
The healthcare industry is primed for expanded adoption of virtual health; a 2016 report estimated that the US virtual health market will reach $3.5 billion in revenues by 2022. Several factors are elevating stakeholder interest, including expected physician shortages, continued growth in digital technologies, changing reimbursement models, increasing consumer demand, and the evolving regulatory landscape. One game-changer: Today, nine in 10 American adults use the internet, giving clinicians the capability and flexibility to communicate with and serve health care consumers via the web.
Zero Sepsis Deaths: A Dialogue of Passion and Practical Wisdom on Sepsis Prev...Health Catalyst
Each year 1.7 million Americans are diagnosed with sepsis, resulting in 270,000 deaths, according to the Centers for Disease Control and Prevention. That’s one death every two minutes, making sepsis the leading cause of death in U.S. hospitals. The financial toll is also high, with the average cost per sepsis stay over $18,000. Sepsis is the number one cause of both initial hospitalizations and readmissions.
Nearly all sepsis deaths are preventable. Community outreach, focused attention on the emergency department, and effective technology and processes to monitor patients already admitted can reduce sepsis mortality. Making a goal of “zero sepsis deaths” a reality is a personal and professional passion of Armando Nahum, a patient activist and co-founder and President of the Safe Care Campaign, and Kathleen Merkley, DNP, ANP, FNP, Senior Vice President of Professional Services at Health Catalyst.
Nahum and Merkley share stories and practical steps to drastically reduce the sepsis toll. Michael L. Millenson, Senior Advisor to Health Catalyst, patient safety expert, and long-time advocate of safer, higher-quality, more patient-centered care, facilitates the dialogue.
What You’ll Learn
- How to implement community outreach to facilitate timely sepsis recognition and seeking of care.
- How to organize emergency department processes for prompt sepsis recognition and treatment.
- How to ensure prompt sepsis recognition and treatment in the inpatient environment.
- How to avoid sepsis readmissions.
Why Accurate Financial Data is Critical for Successful Value TransformationHealth Catalyst
Approximately 50 percent of CMS payments are now tied to a value component. The CMS Innovation Center has allocated nearly $5.4 billion to implement 37 value-based payment models, with 55 percent of those funds marked for development and implementation of additional value-based models. The shift towards value and consumerism is pushing providers to adopt a novel financial mindset and strategy. The key component? Accurate financial data.
In this webinar Steve Vance, senior vice president and executive advisor at Health Catalyst, explores why accurate financial data, coupled with specific tools and strategies, is critical for successful transformation.
View this webinar for key insights into thriving in a value-based environment:
- Why it’s time to embrace new payment methodologies.
- What role financial and clinical data play in value- and risk-based contracts.
- Various organizational and operational strategies for successful financial transformation.
- How Health Catalyst solutions support an innovative data-driven financial process.
Digital Solutions putting the patient at the forefront of Risk ManagementMyMeds&Me
Capturing relevant, essential and complete data at the first interaction
Why surfacing targeted questions and FAQs in-stream maximises the value of the initial contact and reduces low-value follow up.
Digital solutions ensure your REMS and RMP commitments are met with appropriate evidence
How to Use Data to Improve Patient Safety: A Two-Part DiscussionHealth Catalyst
As healthcare organizations continue to experience expenses growing faster than revenues, value based care, and consumer transparency of costs and quality, patient safety will be an important determinant of success. This session will describe the sociotechnical attributes of a safe system, the challenges, the barriers and opportunities, and how to use data and your culture of safety as a powerful tool to drive down adverse events.
Attendees will learn:
Why patient safety and quality are important.
How data can help improve patient safety.
The history of patient safety and where we are today.
What components make up a safety analytics culture.
How the internal safety culture directly impacts patient safety metrics.
To describe basic guidelines for improving a safety culture with analytics.
NCQA’s Accreditation process provides payers with a comprehensive framework to improve quality of care and services. It allows members and employers to compare health plan performance across various plans and against industry benchmarks. NCQA accreditation has 3 parts – HEDIS, Patient experience CAHPS measures and NCQA standards
Patients recognize the benefits of technology-enhanced care, yet only 1 out of 10 use remote patient monitoring today. Read three keys to adoption. https://accntu.re/3fnEy6r
Providers need to move towards real-time analytics that have become critical to demonstrate their quality of care, as reimbursement by government programs can be contingent upon how providers are measured in “Quality of Care”. For example, the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015, also called the Permanent Doc Fix, changes the way Medicare doctors are reimbursed with the implementation of a merit based incentive. The performance-based pressure is huge, which makes it imperative that every provider consider technology solutions. Read more at https://www.solix.com/solutions/data-driven-solutions/healthcare/
Three Strategies to Deliver Patient-Centered Care in the Next NormalHealth Catalyst
Juggling financial demands, uncertain healthcare legislation, and COVID-19 can distract healthcare leaders from the most important aspect of care—patients. Delivering patient-centered care in this volatile market can be challenging, especially when traditional healthcare methods (e.g., in-person visits) are on hold. These sudden disruptions to routine care have highlighted the importance of keeping patients at the center of care, whether care delivery is in-person or virtual. Health systems can manage competing priorities, adjust to pandemic-induced changes, and deliver patient-centered care by focusing on three strategies:
Improve the patient experience.
Implement the Meaningful Measures Initiative.
Transition in-person visits to virtual.
United States Diagnostics Market Size, Share, Trend and Forecast 2026 | TechS...TechSci Research
According to #TechSci Research report, United States Diagnostics Market stood at USD30.08billion in 2020 and is expected to grow at a steady rate of 5.17% during the forecast period.
Gain More Insight: https://bit.ly/3wWI0do
Get Sample Report: https://bit.ly/3ltFdo6
Website: https://www.techsciresearch.com/
Market Research News: https://techsciblog.com/
Opportunity analysis uses data to identify potential improvement initiatives and quantifies the value of these initiatives—both in terms of patient care benefits and financial impact. This process is an effective way to find unwarranted and costly clinical variation and, in turn, develop strategies to reduce it, improving outcomes and saving costs along the way. Standardizing the opportunity analysis process makes it repeatable and prioritizes actionable opportunities.
Quarterly opportunity analysis should follow four steps:
Kicking off the analysis by getting analysts together to do preliminary analysis and brainstorm.
Engaging with clinicians to identify opportunities and, in the process, get clinician buy in.
Digging deeper into the suggested opportunities to prioritize those that offer the greatest benefits.
Presenting findings to the decision makers.
Introducing the Health Catalyst Monitor™ Patient Safety Suite Surveillance Mo...Health Catalyst
Unlike the standard post-event reporting process, the Patient Safety Monitor Suite: Surveillance Module is a trigger-based surveillance system, enabled by the unique industry-first technological capabilities of the Health Catalyst Data Operating System platform, including predictive analytic models and AI. Additionally, once listed, the Health Catalyst PSO will create a secure and safe environment where clients can collect and analyze patient safety events to learn and improve, free from fear of litigation. Coupled with patient safety services, an organization’s active all-cause harm patient safety system is fully enabled to deliver measurable and meaningful improvements.
Good surfers are the consummate analysts. They dynamically process streams of seemingly unrelated information bypassing lesser opportunities, then strategically selecting the perfect wave.
The ability to tease out genuine opportunities amidst a tumult of noise is a hallmark of great analysts. By viewing these slides you will learn:
- The human elements of a great analyst.
- How to re-frame the role of technology in analysis.
- Healthcare knowledge required to maximize the value of a healthcare analyst.
John Wadsworth's (Senior Vice President of Client Engagement, Health Catalyst) engaging presentation style leverages simple and fun analogies to galvanize key concepts for technical, clinical, and executive audiences alike. Join us as he brings principles from the world of surfing and applies them to healthcare analytics.
At eClinicalWorks, we are 5,000 employees dedicated to improving healthcare together with our customers. More than 130,000 physicians nationwide — and more than 850,000 medical professionals around the globe — rely upon us for comprehensive clinical documentation, along with solutions for Practice Management, Population Health, Patient Engagement, and Revenue Cycle Management.
Transforming Clinical Practice InitiativeCitiusTech
The Transforming Clinical Practice Initiative (TCPI) is designed to help small practices and clinicians achieve large-scale health transformation. The initiative is designed to support more than 140,000 clinician practices over four years duration in sharing, adapting and further developing their comprehensive quality improvement strategies. The TCPI is one part of a unique strategy advanced by the Affordable Care Act to strengthen the quality of patient care and manage health care expenditures, ultimately saving the taxpayer from substantial costs. This document describes the initiative in detail with the type of participants, eligibility and reporting requirements of the participants. Understanding the implementation of this initiative not only helps clinicians, but opens up a huge market for Healthcare IT companies offering the products and services like EHR implementation, Integration, EHR/ Data Migration, Implementation of HIE etc.
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
Technology is slowly but surely penetrating the healthcare industry in general and the clinical trials sector in particular. New and advanced solutions offer a variety of possibilities aimed to both improving existing processes and creating new and more efficient ones. And on top of all stands the desire to make clinical trials more patient centric.
In all of this, even though some of the technologies have yet to mature enough to meet the high quality standards necessary, it is important to know them and begin imagining the promise they hold for clinical trials.
Virtual health is supporting continuing efforts to further humanize health care by extending and expanding the concept of a patient-centric care delivery model into one that is truly life-centric.
Virtual health uses telecommunication and networked technologies to connect clinicians with patients (and with other clinicians) to remotely deliver health care services and support well-being. For providers, committing to virtual health at a personal and organizational level affords ever-increasing opportunities to deliver the right care at the right time in the right place, in a connected and coordinated manner.
By strengthening and facilitating a therapeutic alliance between clinicians and patients, virtual health is an important step on our continuous journey to humanize health care. It works within and around a patient’s life, as opposed to their sickness, to deliver care when, where, and how they need and want it. Also, virtual health works its way into consumers’ daily routines by being embedded in electronic devices associated with living life (e.g., smartphones and personal computers) more so than caring for sickness.
The healthcare industry is primed for expanded adoption of virtual health; a 2016 report estimated that the US virtual health market will reach $3.5 billion in revenues by 2022. Several factors are elevating stakeholder interest, including expected physician shortages, continued growth in digital technologies, changing reimbursement models, increasing consumer demand, and the evolving regulatory landscape. One game-changer: Today, nine in 10 American adults use the internet, giving clinicians the capability and flexibility to communicate with and serve health care consumers via the web.
Zero Sepsis Deaths: A Dialogue of Passion and Practical Wisdom on Sepsis Prev...Health Catalyst
Each year 1.7 million Americans are diagnosed with sepsis, resulting in 270,000 deaths, according to the Centers for Disease Control and Prevention. That’s one death every two minutes, making sepsis the leading cause of death in U.S. hospitals. The financial toll is also high, with the average cost per sepsis stay over $18,000. Sepsis is the number one cause of both initial hospitalizations and readmissions.
Nearly all sepsis deaths are preventable. Community outreach, focused attention on the emergency department, and effective technology and processes to monitor patients already admitted can reduce sepsis mortality. Making a goal of “zero sepsis deaths” a reality is a personal and professional passion of Armando Nahum, a patient activist and co-founder and President of the Safe Care Campaign, and Kathleen Merkley, DNP, ANP, FNP, Senior Vice President of Professional Services at Health Catalyst.
Nahum and Merkley share stories and practical steps to drastically reduce the sepsis toll. Michael L. Millenson, Senior Advisor to Health Catalyst, patient safety expert, and long-time advocate of safer, higher-quality, more patient-centered care, facilitates the dialogue.
What You’ll Learn
- How to implement community outreach to facilitate timely sepsis recognition and seeking of care.
- How to organize emergency department processes for prompt sepsis recognition and treatment.
- How to ensure prompt sepsis recognition and treatment in the inpatient environment.
- How to avoid sepsis readmissions.
Why Accurate Financial Data is Critical for Successful Value TransformationHealth Catalyst
Approximately 50 percent of CMS payments are now tied to a value component. The CMS Innovation Center has allocated nearly $5.4 billion to implement 37 value-based payment models, with 55 percent of those funds marked for development and implementation of additional value-based models. The shift towards value and consumerism is pushing providers to adopt a novel financial mindset and strategy. The key component? Accurate financial data.
In this webinar Steve Vance, senior vice president and executive advisor at Health Catalyst, explores why accurate financial data, coupled with specific tools and strategies, is critical for successful transformation.
View this webinar for key insights into thriving in a value-based environment:
- Why it’s time to embrace new payment methodologies.
- What role financial and clinical data play in value- and risk-based contracts.
- Various organizational and operational strategies for successful financial transformation.
- How Health Catalyst solutions support an innovative data-driven financial process.
Digital Solutions putting the patient at the forefront of Risk ManagementMyMeds&Me
Capturing relevant, essential and complete data at the first interaction
Why surfacing targeted questions and FAQs in-stream maximises the value of the initial contact and reduces low-value follow up.
Digital solutions ensure your REMS and RMP commitments are met with appropriate evidence
How to Use Data to Improve Patient Safety: A Two-Part DiscussionHealth Catalyst
As healthcare organizations continue to experience expenses growing faster than revenues, value based care, and consumer transparency of costs and quality, patient safety will be an important determinant of success. This session will describe the sociotechnical attributes of a safe system, the challenges, the barriers and opportunities, and how to use data and your culture of safety as a powerful tool to drive down adverse events.
Attendees will learn:
Why patient safety and quality are important.
How data can help improve patient safety.
The history of patient safety and where we are today.
What components make up a safety analytics culture.
How the internal safety culture directly impacts patient safety metrics.
To describe basic guidelines for improving a safety culture with analytics.
Pharma challenges - Patient Centricity and Digital CapabilitiesJoana Santos Silva
Today pharma's business model is being challenged. The industry needs to rethink how it creates value. In particular, it needs to connect to patients and caregivers in a meaningful way. It many cases this connection can be guaranteed through digital tools and strategies. This presentation focuses on these challenges and showcases some best practices that are already available in the marketplace.
These are some frequently asked questions in Pharmacovigilance Interview & its Preparation.
"HANDS IN HANDS LEARNING"
FOR ENROLLMENT-
CONTACT US ON-
https://pristynresearch.com/
MAIL ID - pristynresearch@gmail.com
ADDRESS-
1) Parmar Trade Centre, A-wing,105/106, Sadhu Vaswani Chowk, Pune, 411001. Email: info@pristynresearch.com Phone: 09028839789
2)T-21/4 ,Opposite To Expert Global, Garware Stadium Road , Software Technology Park of India(STPI), MIDC, Aurangabad-431001. Email: info@pristynresearch.com Call us: 09607709586
FREQUENTLY ASKED QUESTIONS IN PHARMACOVIGILANCE INTERVIEWS & Its PREPARATIONSJonaid Ali
FREQUENTLY asked questions about pharmacovigilance in an interview. Pharmacovigilance is fastest growing career in these days in the healthcare sector specially for pharmacy students although some corporates allow non pharm candidates also
Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...Health Catalyst
Health Catalyst is excited to announce the Patient Safety Monitor™ Suite: Surveillance Module, the industry’s first comprehensive patient safety application to use predictive and text analytics combined with concurrent clinician review of data to help monitor, detect, predict and prevent threats to patients before harm can occur.
The Patient Safety Monitor Suite leverages AI and machine learning to quickly identify patterns of harm, learn from those patterns, and suggest strategies to eliminate patient safety risks and hazards. This potent combination of AI, machine learning, text analytics and near real-time data from multiple IT systems enables the Patient Safety Monitor Suite to predict harm events and guide clinical interventions while the patient is still in the hospital.
In this webinar you will learn how the Surveillance Module can provide:
* Greater clarity to the types, numbers, and causes of adverse events, enabling leaders to quickly prioritize improvement efforts.
* Improved patient outcomes such as reduced morbidity, mortality, and length-of-stay, and increased quality-of-life and satisfaction.
* Bottom-line cost savings and improved brand recognition related to unnecessary or preventable high-cost care and reduced/eliminated penalties.
* The ability for clinicians and infection preventionists to focus on patient care instead of burdensome manual data extraction, aggregation, and reporting.
PHARMACOVIGILANCE COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...Pristyn Research Solutions
Quick Job interview short guide For Pharma and all Life science jobseekers.All Medical | Biotech |Micro |B.Sc., M.Sc.
These are the commonly asked questions with their answers asked in job interviews. The file was updated in 2022.
https://pristynresearch.com/
MAIL ID - pristynresearch@gmail.com
FACEBOOK- https://www.facebook.com/pristynsolutions
INSTAGRAM- https://www.instagram.com/pristyn_res...
TWITTER- https://twitter.com/Pristynresearch
SLIDESHARE- https://www.slideshare.net/azherkhan5916
LINKEDIN- https://www.linkedin.com/in/pristyn-research-191072119/
ADDRESS-
1) Parmar Trade Centre, A-wing,105/106, Sadhu Vaswani Chowk, Pune, 411001. Email: info@pristynresearch.com Phone: 09028839789
2)T-21/4, Opposite To Expert Global, Garware Stadium Road, Software Technology Park of India(STPI), MIDC, Aurangabad-431001. Email: info@pristynresearch.com Call us: 9028839789
Sample Questions are:
What is Pharmacovigilance (PV)?
What are the objectives of PV?
What is MedDRA?
WHAT ARE THE Role of Drug Safety
Associate?
What should narratives consist of?
What are Data assessments in PV?
Which products are covered by PV?
Methods of signal detection?
Why PV is required after clinical
trial?
What is an Adverse Drug Event (ADE)?
What
is the minimum criterion required
for a valid case according to WHO?
When
do you consider an event to be
serious?
What do you mean by causality?
Types of
Unsolicited reports
Sources of Solicited Reports
Name the core regulatory bodies
What is Volume 9A
What do you know
about E2a, E2b and E2c guidelines?
When do you consider a case to be medically confirmed?
What is CemFlow?
What is the yellow card in PV?
What are Comorbid conditions?
What is a medication error?
What is a signal?
Rechallenge
Dechallenge
What are WHO ART, WHO DD and MedDRA and the difference between them?
What is SUSAR?
Adverse Drug Reaction (ADR)
Effectiveness/risk
harm
Essential medicines
Frequency of ADRs
Individual Case Safety Report
ADR Reporting process in PV
VigiFlow
VigiMed
ABBOTTS
COGNIZANT
I 3 GLOBAL DRUG
SAFETY
LAURUS LABS
PARAXEL
SRISTEK
ACCENTURE
CREST.
I GATE PATNI
COMPUTERS
MAHINDRA
SATYAMBSG
PIRAMAL
SUN
PHARMA
ALEMBIC
DIAGNOSEAR
CH
ICON
MAKROCARE
PPD
SYMOGEN
APC PHARMA.
DR REDDY’S
iMEDGlobal,
MANKIND
QUANTUM
SOLUTIONS
SYNOGEN
APCER
ECRON
ACUNOVA
IMS HEALTH
MEDHIMALAYAS
QUINTILES
TAKE
SOLUTIONS
APCER
EMCURE
INC RESEARCH
MEDPACE.
SCIFORMIX
RATIOPHARM
TCS
ASTRAZENECA
FDC
Infocorp
Soft
Solutions
MICRO LABS
RX MD
THOMSON
REUTERS
AUROBINDO
FORTIS
HEALTH CARE
INVENTIVE
MSD (MERCK)
SANTHA
BIOTECH
USV
LIMITED
BESTOCHEM
G7 INFOTECH
IPCA
LABORATORIES
NEKTAR
THERAPEUTICS
SCIFORMIX.
VIMTA LABS
BIOCAD
GENPACT
IPLEX
NORWICH
CLINICAL SERVICES
SHANTHA
BIOTECHNICS
WIPRO
BIOCON
GRANULES
JUBILIANT
BIOSYS NOVARTIS
SIRO
CLINPHARM
WNS
BIOLOGICAL E.
LTD
GVK
KINAPSE
NOVO NORDISK
SP softtech
WOCKHARD
T
BLUEFISH
HCL
LAMBDA
OMNICARECLINICA
L RESEARCH
SRI KRISHNA
PHARMA
4C
Pharma
Solutions
The Increasing Importance of Patient Reported Outcomes and the Patient Voice ...Covance
Over the past few years there has been a paradigm shift in the overall approach to pharmacovigilance from that of pure safety analysis to overall benefit-risk evaluation of products. **Disclaimer: This article was previously published. Sciformix is now a Covance company.
Twenty-first century technologies will create significant opportunities and challenges for all healthcare stakeholders. Pharmacovigilance (PV) too is in transition, with new sources of medical information and methods for its analysis that will transform today's largely reactive system into proactive benefit-risk management for all medication users.
How to Use Data to Improve Patient Safety: Part 2Health Catalyst
Stan and Valere will discuss how using an automated trigger tool for all-cause harm reviews will provide timely, real-time patient safety data useful to drive down harm rates with earlier interventions. Additional benefits of this approach include having a more accurate and robust source of data for identifying harm trends to then be able to integrate the findings into existing quality improvement processes for further quality improvement efforts.
Attendees will learn how to:
Understand the importance of dedicating resources to impact downstream costs
Identify their key sources of Patient Safety data
Integrate Patient Safety data in to existing Quality Improvement Processes
Learn and improve from real-time safety analytics combined with a Culture of Safety
Qrepublik MedID Presentation Product (NEW)_compressed.pdfQREPUBLIC, INC.
QRepublik Medical ID is a beautifully designed medical ID platform built exclusively for people. We make it easy to medical IDs to thousands of people in the United States and around the world. In emergencies or times of need, we provide members’ critical health and identification information to first responders. This information exchange empowers first responders to act promptly to protect and save lives.
Solutions for B2B &B2C market
QRepublik Medical IDs Product Presentation1.pdfQREPUBLIC, INC.
QRepublik is a beautifully designed medical ID platform built exclusively for people. Comprehensive medical ID solution that provides an easy way to access, store, and manage your health information. Your medical profile can be accessed anytime, anywhere via QRepublik medical ID Products such as bracelets, sticker kits, and sleeves for smartwatches.
The World Health Organization defines pharmacovigilance as the science and actions connected to the detection, evaluation, understanding, and prevention of adverse effects or any other drug related problem. Pharmacovigilance is critical in ensuring that patients receive safe pharmaceuticals. We can learn more about a drugs side effects through a variety of methods, including spontaneous reporting, diligent monitoring, and database research. Novel mechanisms are being established at both the regulatory and scientific levels to increase pharmacovigilance. They include conditional approval and risk management strategies on a regulatory level, and openness and increasing patient engagement on a scientific one. OBJECTIVE To review and discuss various aspects of pharmacovigilance, including new methodological developments. V Sai Kruthika | Sarvani Ekathmika | Prathamesh Golapkar "Advanced Methodologies in Pharmacovigilance" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-2 , April 2023, URL: https://www.ijtsrd.com.com/papers/ijtsrd55052.pdf Paper URL: https://www.ijtsrd.com.com/other-scientific-research-area/other/55052/advanced-methodologies-in-pharmacovigilance/v-sai-kruthika
Similar to Using Digital Innovation to Establish Authentic Reporter Dialogue (20)
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Using Digital Innovation to Establish Authentic Reporter Dialogue
1. USING DIGITAL INNOVATION
TO ESTABLISH AN AUTHENTIC REPORTER DIALOGUE
& TRANSFORM PROCESS EFFICIENCY
DR. ANDREW RUT,
CHIEF EXECUTIVE OFFICER,
MyMeds&Me
Capture Purer Data, Faster
2. “Consider the impact on American services if other industries routinely
operated in the same manner as many aspects of health care:
• If airline travel were like health care, each pilot would be free to design
his or her own preflight safety check, or not to perform one at all. ”
Pharmaceutical Public Policy – Thomas R. Fulda, Alan Lyles, Albert I Wertheimer
3. Digital solutions put the patient at the forefront
of the Safety processes
Capturing relevant, essential and complete data atthe first
interaction
Why surfacing targeted questions and FAQs in-stream
maximises the value of the initial contact and reduces low-value
follow up.
Digital solutions ensure your REMS and RMPcommitments are
met with appropriate evidence
4. AERs across product portfolio or lifecycle
New products
Need fast feedback as complete as
possible to fuel analytics for informed
decisions in a timely & consistent manner.
Established products
High data volumes that need to be processed
in a compliant, automated manner with an
emphasis on product quality. 4
5. • MISSING KEY INFO
• RMP GAPS
• INADEQUATE DATA
• INCOMPLETE B/R PROFILE
N E W P R O D U C T S E S T A B L I S H E D P R O D U C T S
• WARNINGS
• WITHDRAWALS
Economic impact
toPharma Co.
Economic impact
toHealthcare System
• AES TAKEN FOR GRANTED
• ASSUMEDLOW IMPACT
• UNINFORMEDPATIENT
• LACK OF PATIENT ADHERENCE
• DISEASE POORLY TREATED
• HOSPITAL ADMISSIONS
The Convention
Inadequate or
ignored data
LOW VALUE AERS
STABLE RISK/BENEFIT
HIGH VALUE AERS
EVOLVING RISK/BENEFIT
6. Missed Opportunity: Data has to be obtained first time at
source
Current systems are not working to capture data on AERs;
Targeted follow-up is failing
The impact is profound on the product, patients and the
healthcare system
No amount of post-processing by PV Professionals or AI tools
can rectify deficiencies of data quality
7. “
”
Adverse drug events (ADEs) arean increasingly
relevant issue for healthcare systems as they are
associated with poorer health outcomes and
avoidable misuse of resources
The EconomicBurden ofInappropriateDrug Prescribing,Lack ofAdherence andCompliance, AdverseDrug EventsinOlder
People;ASystematicReview;CarlosChiatti,1SilviaBustacchini,1GianlucaFurneri,1LorenzoMantovani,2Marco
Cristiani,3ClementinaMisuraca4andFabriziaLattanzio
8. H ea l th c a r e b u r d en o f ADR s
3.7% 39% 40%
ADRs accountfor 3.7%
of hospitaladmissions
inthe Developedworld.
~39% of ADRs in
pediatricpatientscanbe
life threateningor fatal.
Non-adherence
Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to
hospital? A systematic review. Br J Clin Pharmacol. 2007;63:136–47.
9. Non-adherenc e and AERs: ART for HIV
Patients with specific AEs were significantly less likely to adhere
to ART compared to patients without these Adverse events:
Confusion OR= 0.349;
Taste disturbances OR= 0.485;
Nausea OR = 0.574;
The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic
review and meta-analysis Imad Al-Dakkak, Seema Patel, Eilish McCann, Abhijit Gadkari, Girish Prajapati, and Eric
M. Maiese
10. So how do Regulatory agencies try to address
these challenges?
FDA - REMS
EMA - RMPs
PMDA- PMS
11. The FDA most often determined that REMS were not
meeting their goals because of deficiencies in patient and
prescriber awareness of drug risks.
Pharmaceuticalpublicpolicy:Fulda,Lyles&Wertheimer; CRCPress2016
12. Targeted Follow u p Qu estion n aires
50% 20% 10%
Sent out as
required
Returned Contain Useful or
legible f/u
information
14. “
”Factors related to high and low levels of drug adherence according to patients with type 2 diabetes Sander
D. Borgsteede, Marjan J. Westerman,3 Irene L. Kok,1 Joke C. Meeuse,1 Theo P. G. M. de Vries,1 andJacqueline
G. Hugtenburg1
Medicines are prescribed, I use them. That’s it. I never read
the package leaflet. When you read it, you lose courage to
use them any longer, and in my opinion you have to use
them… the colours tell me how: blue is for the prostate,
and I have orange and white, and for my sugar I use a
tablet somewhat larger. ……..
Knowledgeaboutmedication?I have no idea
15. “
”
Almost impossible. Cannot be statins. Not
possible. Denied possibility. CPK didn’t indicate
statin-related adverse effect.
Doctor said there were no side effects. Can’t be
the statins, thinks it is a miracle drug
Dismissed relationto drug
Source: Beatrice A. Golomb et al, Physician Response to Patient Reports of Adverse Drug
Effects Implications For Patient-Targeted Adverse Effect Surveillance, Drug Safety 2007
17. Data Quality: vigiGrade….Focus on the Intake
ICSR value is directly proportional to the amount of clinically
relevant information they include.
Overall, only 12% reports provide the desired level of
information
Physicians consumers using e-reporting tools also
generate greater proportions of well-documented reports
overall
vigiGrade: A Tool to IdentifyWell-DocumentedIndividual Case Reports and Highlight Systematic Data Quality Issues
Tomas Bergvall • G. Niklas Nore´n • Marie Lindquist
18. B e t t e r c a s e i n f o r m a t i o n
> b e t t e r s i g n a l d e t e c t i o n
Strengthof evidence:vigiRank
• ‘Informative Reports have
greatest impact’
Improved Statistical Signal Detection in Pharmacovigilanceby Combining
Multiple Strength-of-Evidence Aspects in vigiRank -Retrospective Evaluation
against Emerging Safety Signals
Ola Caster, Kristina Juhlin, Sarah Watson & G. Niklas Norén
19. Reportum: Industry Standard SaaS capture solution for Adverse
Events & Product Complaints
Configurable web/mobile platform for dynamic data capture in real
time including targeted Qs
Multi-language, includes f/u processing and linked toLearning
management systems
Active workflow with QC and auto-reconciliation delivers coded ICSRs
and PQCs
21. Pa ti en t i n c o n tr o l o f a vi r tu o u s c yc l e
Informed
patient
Compliance with
Label
Benefitsquantified
Risksidentified&
contextualized
AlertstoPhysicianor
Pharmateam
concerningSAE/AESI
Label & PILeaflet
updated Ongoing
assessment
and comms. of
benefit-risk
Rapid
identification
of issues with
automated
triage
24. AI combined with
Reportum
• Manages any remaining
unstructureddata
• Createslearning system
• Leverages the benefits of Reportum
business processes
Enables additional process automation:
25. • ROBUST B/R ASSESSMENT
N E W P R O D U C T S E S T A B L I S H E D P R O D U C T S
Accurate product
label
Optimised Healthcare
• COMPLIANT
• AUTOMATED/ STREAMLINED
• DRUG ADHERENCE
• FAST
• RELEVANT / COMPLETE
Purer data
I N F O R M E D P A T I E N T
D I G I T A L P R O D U C T S• ENRICHED SIGNAL DETECTION • EMPHASIS ON QUALITY
• DRUG INTERACTIONS